Wedbush Forecasts Weaker Earnings for Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. (TSE:FRX) – Wedbush reduced their FY2025 earnings per share estimates for Fennec Pharmaceuticals in a research note issued on Thursday, August 14th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings of $0.44 per share for the year, down from their prior estimate of $0.59. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. Wedbush also issued estimates for Fennec Pharmaceuticals’ Q4 2025 earnings at $0.10 EPS.

Fennec Pharmaceuticals Stock Up 4.2%

Shares of Fennec Pharmaceuticals stock opened at C$11.84 on Monday. Fennec Pharmaceuticals has a 1 year low of C$5.65 and a 1 year high of C$12.99. The company has a market cap of C$228.33 million, a P/E ratio of -200.57 and a beta of 0.25. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83. The stock has a 50-day moving average price of C$11.53 and a 200 day moving average price of C$9.94.

Insider Transactions at Fennec Pharmaceuticals

In related news, Director Rostislav Christov Raykov sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of C$11.71, for a total transaction of C$117,096.00. Also, Senior Officer Robert Christopher Andrade acquired 8,220 shares of the company’s stock in a transaction on Monday, June 2nd. The stock was bought at an average price of C$6.99 per share, for a total transaction of C$57,433.14. Insiders sold a total of 23,246 shares of company stock worth $243,883 in the last quarter. 16.20% of the stock is owned by corporate insiders.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.